These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 34064508)

  • 1. Vascular Endothelial Growth Factor, a Key Modulator of the Anti-Tumor Immune Response.
    Geindreau M; Ghiringhelli F; Bruchard M
    Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34064508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
    Zhao Y; Adjei AA
    Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Review of Anti-Angiogenic Targets for Monoclonal Antibody Cancer Therapy.
    Kong DH; Kim MR; Jang JH; Na HJ; Lee S
    Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28817103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring the Benefit/Risk Associated with Antiangiogenic Agents for the Treatment of Non-Small Cell Lung Cancer Patients.
    Kurzrock R; Stewart DJ
    Clin Cancer Res; 2017 Mar; 23(5):1137-1148. PubMed ID: 27940520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab.
    Papadopoulos N; Martin J; Ruan Q; Rafique A; Rosconi MP; Shi E; Pyles EA; Yancopoulos GD; Stahl N; Wiegand SJ
    Angiogenesis; 2012 Jun; 15(2):171-85. PubMed ID: 22302382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor angiogenesis and anti-angiogenic therapies.
    Shahneh FZ; Baradaran B; Zamani F; Aghebati-Maleki L
    Hum Antibodies; 2013; 22(1-2):15-9. PubMed ID: 24284305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications.
    Ferrara N
    Semin Oncol; 2002 Dec; 29(6 Suppl 16):10-4. PubMed ID: 12516033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma.
    Patterson DM; Gao D; Trahan DN; Johnson BA; Ludwig A; Barbieri E; Chen Z; Diaz-Miron J; Vassilev L; Shohet JM; Kim ES
    Angiogenesis; 2011 Sep; 14(3):255-66. PubMed ID: 21484514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiogenesis regulated by VEGF and its receptors and its clinical application.
    Shibuya M
    Rinsho Ketsueki; 2009 May; 50(5):404-12. PubMed ID: 19483401
    [No Abstract]   [Full Text] [Related]  

  • 10. Anti-Angiogenic Drugs, Vascular Toxicity and Thromboembolism in Solid Cancer.
    Riondino S; Del Monte G; Fratangeli F; Guadagni F; Roselli M; Ferroni P
    Cardiovasc Hematol Agents Med Chem; 2017; 15(1):3-16. PubMed ID: 28137223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-vascular endothelial growth factor therapy in breast cancer: Molecular pathway, potential targets, and current treatment strategies.
    Zhang M; Liu J; Liu G; Xing Z; Jia Z; Li J; Wang W; Wang J; Qin L; Wang X; Wang X
    Cancer Lett; 2021 Nov; 520():422-433. PubMed ID: 34389434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The VEGF signaling pathway in cancer: the road ahead.
    Stacker SA; Achen MG
    Chin J Cancer; 2013 Jun; 32(6):297-302. PubMed ID: 23419196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The anti-vascular endothelial growth factor receptor-1 monoclonal antibody D16F7 inhibits invasiveness of human glioblastoma and glioblastoma stem cells.
    Atzori MG; Tentori L; Ruffini F; Ceci C; Lisi L; Bonanno E; Scimeca M; Eskilsson E; Daubon T; Miletic H; Ricci Vitiani L; Pallini R; Navarra P; Bjerkvig R; D'Atri S; Lacal PM; Graziani G
    J Exp Clin Cancer Res; 2017 Aug; 36(1):106. PubMed ID: 28797294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular endothelial growth factor inhibitors in colon cancer.
    Díaz-Rubio E
    Adv Exp Med Biol; 2006; 587():251-75. PubMed ID: 17163170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does the addition of drugs targeting the vascular endothelial growth factor pathway to first-line chemotherapy increase complete response? A meta-analysis of randomized clinical trials.
    Li Y; Liang XY; Yue YQ; Sheng L; Liu JK; Wang ZY; Chen G
    Tumour Biol; 2016 May; 37(5):6297-306. PubMed ID: 26619847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Role of VEGF in diseases of the retina].
    Barquet LA
    Arch Soc Esp Oftalmol; 2015 Mar; 90 Suppl 1():3-5. PubMed ID: 25925044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy.
    Ferrara N; Hillan KJ; Novotny W
    Biochem Biophys Res Commun; 2005 Jul; 333(2):328-35. PubMed ID: 15961063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular endothelial growth factor as a therapeutic target in cancer.
    Bergsland EK
    Am J Health Syst Pharm; 2004 Nov; 61(21 Suppl 5):S4-11. PubMed ID: 15552621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors.
    Homsi J; Daud AI
    Cancer Control; 2007 Jul; 14(3):285-94. PubMed ID: 17615535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts.
    Roland CL; Dineen SP; Lynn KD; Sullivan LA; Dellinger MT; Sadegh L; Sullivan JP; Shames DS; Brekken RA
    Mol Cancer Ther; 2009 Jul; 8(7):1761-71. PubMed ID: 19567820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.